Approval · Notice of Compliance 30521 · 2023
BRIVLERA: Notice of Compliance 30521
Issued April 14, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30521
- Date
- April 14, 2023
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Warning and Precautions and Patient Medication Information sections of the Product Monograph (PM).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BRIVLERA | Not yet assigned | — |
Medicinal ingredients
- BRIVARACETAM 10 MG per TAB
- BRIVARACETAM 25 MG per TAB
- BRIVARACETAM 50 MG per TAB
- BRIVARACETAM 75 MG per TAB
- BRIVARACETAM 100 MG per TAB
- BRIVARACETAM 10 MG per ML